Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.


10


Reuters

18 Related Articles from 2018-09-26